THE FIRST DESCRIPTION OF BIlateral
|
|
- Domenic Shields
- 6 years ago
- Views:
Transcription
1 CLINICAL SCIENCES Clinical Course of Optic Neuritis in Patients With Relapsing Neuromyelitis Optica Regina Maria Papais-Alvarenga, MD, MSc, PhD; Sandro Carvalho Carellos, MD, MSc; Marcos Papais Alvarenga, MD; Clarice Holander, MD; Roberly Pinto Bichara, MD, MSc; Luiz Claudio Santos Thuler, MD, MSc, PhD Objective: To describe the clinical characteristics, course, and prognosis of optic neuritis in recurrent neuromyelitis optica. Methods: We analyzed 60 patients diagnosed using 1999 Mayo Clinic criteria who were seen between 1985 and 2004 at Hospital da Lagoa (Rio de Janeiro, Brazil). Results: Optic neuritis was the initial feature in 53.3% of patients, most with unilateral disease. Recurrent optic neuritis before myelitis occurred in 18.3%. The visual impairment was severe at nadir of the visual index event in 78.3%, with a high remission rate. In the median disease duration of 8 years (range, years), 380 relapses (118 optic neuritis, 223 myelitis, 39 optic neuritis and myelitis) occurred. At the last follow-up, 53.3% of patients had bilateral visual impairment and 63.3% were blind in at least 1 eye. A high mortality rate (23.3%) was due to cervical myelitis. Mortality rates were significantly higher among Afro Brazilian patients (58.3%). Conclusions: Optic neuritis in patients with recurrent neuromyelitis optica has a severe and acute onset, with predominantly unilateral lesions followed by improvement of clinical symptoms. In the long-term, the disease leads to severe bilateral visual impairment. Mortality rates are higher among patients of Afro Brazilian descent. Arch Ophthalmol. 2008;126(1):12-16 Author Affiliations: Neurology Service (Dr R. M. Papais-Alvarenga) and Ophthalmology Service (Drs Holander and Bichara), Hospital da Lagoa, Postgraduation Program (Master of Science in Neurology), Universidade Federal do Estado do Rio de Janeiro (UNIRIO) (Drs R. M. Papais-Alvarenga, Carellos, M. P. Alvarenga, and Thuler), and Instituto Nacional de Câncer (INCA) (Dr Thuler), Rio de Janeiro, Brazil. THE FIRST DESCRIPTION OF BIlateral amaurosis associated with subacute myelitis and a fatal course was provided by Eugène Devic at the end of the 19th century in Lyon, France. 1 For more than a century, these clinical parameters were the basis for the diagnosis of a rare neurological disease restricted to the optic nerve and spinal cord, called neuromyelitis optica (NMO) or Devic disease. 2 At For editorial comment see page 128 present, this condition is classified as an idiopathic inflammatory demyelinating disease of the central nervous system (CNS). 3 Based on case studies published in different countries within the last decade, 4-8 a relapsing type of NMO (RNMO) was identified. It is clinically characterized by 2 index events (optic neuritis [ON] and transverse myelitis [TM]) separated by an interval of days, weeks, months, and even years, with variable remission followed by new clinical events restricted to the optic nerve and spinal cord. 5. In 1999, Wingerchuk et al 5 from the Mayo Clinic proposed diagnostic criteria for NMO with the aim of differentiating between this condition and multiple sclerosis (MS), the most common demyelinating disorder with a relapsing-remitting clinical course. Magnetic resonance imaging (MRI) of the brain and spinal cord as well as cerebral spinal fluid (CSF) analysis were the complementary methods indicated for laboratory support. IgG oligoclonal bands in CSF and multiple brain MRI lesions that are typical in MS are uncommon in NMO. Monophasic NMO often occurs after infections or vaccinations. 5,6 Relapsing NMO is an immunomediated disease that especially involves humoral mechanisms. 9,10 Identification of an NMO-specific IgG antibody in the sera of patients with NMO 11 brought new support for the hypothesis that RNMO is distinct from MS, despite its recurrent clinical course. In this article, we will describe the clinical course of ON in a series of patients with RNMO from the Hospital da Lagoa, a referral center for the treatment of demyelinating disorders in Rio de Janeiro, Brazil. METHODS Eighty-two cases of ON and TM were identified from a group of 640 cases of demyelinating disease of the CNS. The cohort was followed up 12
2 Table 1. Quantification of Optic Nerve Impairment 5 and Correlation Between VA and Percentage of Visual Loss 13 Ordinal Scale Score Description of Visual Function between 1985 and 2004 at the Hospital de Lagoa, a public tertiary hospital in Rio de Janeiro run by the Ministry of Health that is a referral center for patients with MS. From a database (SIAPEM 12 ) and medical files, we extracted clinical data and complementary examination results (MRI of the brain and spinal cord and CSF analysis) in order to apply the 1999 Mayo Clinic diagnostic criteria for NMO, which require the presence of all absolute criteria and 1 major supportive criterion or 2 minor supportive criteria. 5 By case definition, NMO with recurrent clinical course is clinically characterized by 2 index events (ON and TM) with variable remission followed by new clinical events restricted to the optic nerve and spinal cord. Twenty-two cases were excluded, 8 of them because of monophasic course. All patients had their visual function evaluated by measuring visual acuity (corrected) using the Snellen card. Testing of the optic fundi, direct and consensual pupillary reflexes, and visual evoked potentials as well as a routine ophthalmological examination and manual campimetric test were done. An ordinal scale 5 devised to quantify optic nerve impairment in patients with NMO (Table 1) was applied. We classified the visual impairment into 3 categories: severe (visual loss 80%), moderate (visual loss 79%-35%), and mild (visual loss 34%), according to the percentage of visual loss efficiency for distance (20 ft) in correspondence to Snellen notations (American Medical Association standards). 13 An ambidirectional cohort study was conducted based on the analysis of the clinical course of ON in patients with RNMO. The results of the categorical variable analysis were presented as percentages and those concerning the continual variables were presented as averages, followed by the minimum and maximum values. The percentages reflect valid numbers that are a product of the exclusion of the missing values. The statistical significance of the differences observed between the dichotomous variables was analyzed using Pearson or Fisher 2 tests, as indicated. The analysis of the progression time frame of the disease as well as the survival time frame was done with the help of Kaplan-Meier curves. We considered all P values.05 as statistically significant. The information was analyzed using SPSS for Windows (version 14.01; SPSS Inc, Chicago, Illinois). The research project was approved by the Ethics and Research Committee of the Hospital Universitário Gafrée e Guinle, Universidade Federal do Estado do Rio de Janeiro. RESULTS Estimate of Visual Loss, % 0 Normal VA 1 Scotoma, but VA (corrected) 20/ VA (corrected) 20/30-20/ VA (corrected) 20/60-20/ VA (corrected) 20/200-20/ Counting fingers 6 Light perception 7 No light perception 8 Unknown Abbreviation: VA, visual acuity. Table 2. Frequency of Absolute and Supportive Criteria for NMO 5a No. (%) of Patients Absolute criteria Optic neuritis 60 (100.0) Acute myelitis 60 (100.0) No clinical evidence of disease outside of the 60 (100.0) optic nerve or spinal cord Supportive criteria Major Normal brain MRI at onset (that does not 46 (100.0) met Paty criteria 14 ) Spinal cord MRI with signal abnormality extending 54 (87.0) b over 3 vertebral segments Pleocytosis in the CSF 50 cells/mm 3 or 5 (17.2) 5 neutrophils/mm 3 Minor Bilateral optic neuritis 47 (78.3) Severe optic neuritis with fixed visual acuity 42 (70.0) 20/200 in at least 1 eye Severe, fixed, attack-related weakness 26 (43.3) (MRC grade 2) in 1 limbs Abbreviations: CSF, cerebrospinal fluid; MRC, Medical Research Council; MRI, magnetic resonance imaging; NMO, neuromyelitis optica. a Data source: SIAPEM database. 12 b Spinal cord MRI showed multiple lesions in fewer than 3 vertebral segments in 4 patients (7.4%) and 1 lesion in fewer than 3 vertebral segments in 1 patient (1.8%) and was normal in 2 patients (3.7%) after intravenous methylprednisolone treatment. We selected for this study 60 patients with relapses after the index events (ON and TM) that fulfilled the diagnostic criteria. Table 2 elucidates the frequency of absolute, major, and minor supportive criteria presented in this series. Epidemiological and clinical characteristics of the patients are presented in Table 3. The female-male ratio was 9:1 and 58.3% were of Afro Brazilian ethnicity (black and mixed race). Most of these patients (63%) sought the Hospital da Lagoa by spontaneous demand or by referral from other medical services; 30% of patients were originally seen in private practices by neurologists belonging to the Hospital da Lagoa team and were invited to participate in the study, while the other 7% came from other states in search of a definitive diagnosis for their condition. IsolatedONwastheinitialfeaturein32patients, ofwhom 11 had 2 or more visual events before conversion to NMO. Demographic and clinical characteristics of patients with a single visual event at onset (n=11) were indistinguishable from those with recurrent ON (n=21) except for the median age at onset (isolated ON, 25 years; recurrent ON, 35 years) and a shorter median interval between the first visual event and the occurrence of myelitis (isolated ON, 8 months; recurrent ON, 34 months) (data not shown). In the most severe phase of the visual index event, 65% of patients showed signs of unilateral visual damage and 35% showed signs of bilateral damage. There was severe loss of vision (visual acuity 20/200) in at least 1 eye in 78.3% of patients, followed by spontaneous remission or remission through the use of corticosteroids. However, severe visual deficits remained in 35% of patients. Figure 1 shows the evaluation of visual impairment conducted at the nadir and at the best recovery of the visual index event and at the last follow-up according to an or- 13
3 Table 3. Epidemiological and Clinical Characteristics of 60 Patients With Relapsing Neuromyelitis Optica a No. (%) of Characteristic Patients Sex M 6 (10.0) F 54 (90.0) Age at disease onset, y (20.0) (55.0) (23.3) 60 1 (1.7) Race/ethnicity White 25 (41.7) Mixed race 18 (30) Black 17 (28.3) City of origin Rio de Janeiro, Brazil 50 (83.3) Other 10 (16.7) Socioeconomic status A (highest level) 7 (11.7) B 17 (28.3) C 18 (30.0) D 15 (25.0) E (lowest level) 3 (5.0) Clinical manifestations at onset Transverse myelitis 26 (43.3) Unilateral optic neuritis 21 (35.0) Bilateral optic neuritis 11 (18.3) Transverse myelitis and unilateral optic neuritis 1 (1.7) Transverse myelitis and bilateral optic neuritis 1 (1.7) Clinical manifestations during the course of the disease Transverse myelitis 223 (58.7) Optic neuritis 118 (31.0) Transverse myelitis and optic neuritis 39 (10.3) a Data source: SIAPEM database. 12 dinal scale (Table 1). 5 At the last follow-up, 50 patients showed signs of visual impairment (18 unilateral and 32 bilateral) and the following scores were identified: score 0 (normal vision) in 16.7% of patients; score 1 in 5.0%; score 2 in 8.3%; score 3 in 6.7%; score 4 in 13.3%; score 5 in 6.7%; score 6 in 20.0%; and score 7 in 23.3%. The median score for the classification of the visual deficit was 7 in the most severe phase of the index event, 2 in the remission phase, and 4 in the last follow-up. When we compared the rates of severe visual dysfunction (loss of vision 80%) observed in the most severe phase of the index event (78.3%) and in the remission phase (35.0%), a statistically significant difference was observed (P.001). However, when we compared the difference between the rate of severe visual dysfunction in the most severe phase of the index event (78.3%) and the final evaluation (63.3%), we did not get a statistically significant value (P=.07). Furthermore, ocular pain was mentioned in the clinical histories of 27% of patients. The median disease duration at the last follow-up was 8 years (6 months-30 years). The median number of events per patient was 5 (range, 3-18 per patient). Acute TM was the most common event (58.7%), followed by visual events (31.0%) and optical spinal syndromes occurring in the same day (10.3%), as shown in Table 3. Concerning the evolution of the visual impairment, the median time for the occurrence of 80% or more visual loss in 1 eye (visual score=4), observed in 37 patients (61.7%), was 0.08 years (1 month), varying between (1 day) and 26 years; complete loss of vision (score 6) in both eyes was observed in 22 patients (36.7%) and occurred in a median of 2.0 years, varying between 0.25 (3 months) and 30 years (Figure 2). The occurrence of 80% or more visual loss in 1 eye (white Brazilian patients, 40.0% vs Afro Brazilian patients, 77.1%; P=.004) and in both eyes (16.0% vs 72.0%, respectively; P=.004) were statistically different according to race. Finally, there were 14 deaths (23.3%), and the median survival was 8 years (range, 1-30 years). The cause of death was directly related to cervical spinal cord damage with tetraplegia and respiratory failure in 13 patients (92.9%). Of the 14 patients whose course ended in death, 12 were Afro Brazilian and 2 were white. These numbers lead to a 34.3% mortality rate among Afro Brazilian patients and 8.0% among white Brazilian patients, a difference that is statistically significant (P=.02). COMMENT The diagnosis of idiopathic ON, as well as all the inflammatory demyelinating syndromes, depends on the exclusion of vascular, infectious, degenerative, metabolic, and tumoral diseases. 15 In some patients, ON manifests by a single episode (monophasic ON) or develops into outbreaks and remissions (recurrent ON), but it could also be the onset manifestation of MS or the index event of NMO. 3 In 1991, the Optic Neuritis Treatment Trial 16 presented the results of its analysis of the clinical profile of demyelinating ON in 448 American patients (77.2%, female; 85%, white). The acute phase was characterized by alteration of visual acuity (85.9%) and ocular pain (92.2%). The median visual acuity was 20/60 and severe visual loss ( 20/200) occurred in only 35.9% of cases. One-third of the patients developed MS. Phillips et al 17 compared clinical characteristics of demyelinating ON in black and white patients seen between 1989 and 1996 in the United States. They concluded that visual acuity was more severely affected in African American individuals, both in the initial phase of the disease and in the period 1 year later. Furthermore, the African American individuals with initial-phase ON that evolved into demyelinating disease most often developed NMO. The natural history to recurrent ON was described by Pirko et al 18 in a series of 72 patients. The 5-year conversion rate to NMO was 12.5% and to MS was 14.4%. The comparison among clinical and demographical characteristics of nonconverters (40 of 72), converters to NMO (8 of 72), and converters to MS (20 of 72) showed in the NMO group a high female-male ratio (7:1) and the greatest final visual impairment. Herein, the spectrum and natural history of ON in relapsing NMO was described from a longitudinal analysis of a large series of patients from Rio de Janeiro. Most of the patients were female and Afro Brazilian. Development of the disease occurred between 30 and 40 years of age. Severe isolated unilateral ON was the initial mani- 14
4 70 60 Most severe Remission Last follow-up 50 Percentage Visual Function Score Figure 1. Quantification of optic nerve impairment by an ordinal scale 5 (Table 1) in the most severe phase of remission of the visual index event and at the last evaluation (n=60). Scores indicate the following: 0, normal visual acuity (VA); 1, corrected VA better than 20/30; 2, VA 20/30 to 20/59; 3, VA 20/60 to 20/199; 4, VA 20/200 to 20/800; 5, counting fingers; 6, light perception; and 7, no light perception. Data source: SIAPEM database. 12 A 1.0 B Cumulative Survival Cumulative Survival Time, y Time, y Figure 2. Progression of optic nerve impairment. A, Time to 80% or more visual loss in 1 eye (visual score=4) (n=60). B, Time to bilateral loss of vision (visual score 6) (n=60). Data source: SIAPEM database. 12 festation of the disease in most of the patients. Few patients had recurrent visual events before conversion to NMO. As is characteristic of the natural course of inflammatory CNS disease, a high rate of remission took place spontaneously or after the use of corticosteroids following the first optic event. However, two-thirds of the patients developed severe unilateral visual impairment after a short period of disease, one-third had bilateral amaurosis in a median time of 2 years, and most patients had severe visual damage in at least 1 eye at the last follow-up, thereby confirming the high morbidity of ON. Considering the ethnic characteristics of the population, ON morbidity and mortality were significantly greater in Afro Brazilian patients. We found a low frequency of ocular pain (27%) in the medical records. However, most of the patients with retrobulbar neuritis had retro-orbital pain or ocular pain related to eye movement. 19 Reviewing 8 case studies of patients with ON published between 1904 and 1994, Volpe 20 found a prevalence of ocular pain that varied between 33% and 92%. In 2005, Agostoni et al 19 called attention to the difficulty of evaluating pain in patients with ON. They said that in clinical practice, ON is diagnosed mostly by ophthalmologists and less frequently by neurologists. They emphasize that although pain is the bedrock of this diagnosis, it is often neglected by patients and by physicians. One limitation of the present study is that most of the information obtained concerning the initial events was done retrospectively. It is clear from the clinical descriptions that the attention of both the specialists and the patients was directed toward the loss of vision, with no emphasis on ocular pain, which may explain its low prevalence in this case study (27%). Optic neuritis as a clinical event of NMO has been previously analyzed in other case studies. 4-8 O Riordan et al 4 described in London 10 of 12 patients (83.3%) with a severe loss of vision (the patients could not count fingers). Wingerchuk et al 5 analyzed the visual acuity at the last available assessment of 43 patients with relapsing disease at the Mayo Clinic and found complete blindness (acuity 20/ 200) in at least 1 eye in 60%. Papais-Alvarenga et al 6 pro- 15
5 spectively studied 24 Brazilian patients (22 with recurrent disease) and found, at last follow-up, permanent visual loss in 63% (unilateral in 21% and bilateral in 42%). De Seze et al 7 described 13 French patients diagnosed with NMO during the period of 1985 through 1999, 10 of them with a relapsing-remitting pattern. The initial symptom was ON in only 2 cases; ON was bilateral at onset in 11 patients. After a mean period of 8.6 years, 53% had severe abnormalities in visual function (visual acuity 20/200). The Italian Devic s Study Group 8 gathered 46 patients in a multicenter study in They found that the initial event was unilateral ON in 37.0%, bilateral ON in 19.6%, and simultaneous myelitis and ON in 4.5%; in the remainder of the group, the onset of the disease was myelitis. The recurrent type of NMO, clinically characterized by ON and TM followed by new clinical events restricted to the optic nerve and spinal cord, has been clearly recognized as distinct from MS in the last decade. 5 Wingerchuk et al 5 analyzed 71 patients, 23 with monophasic-type disease and 48 with recurrent-type disease, who were seen between 1951 and 1992 and clearly distinguished the clinical course and outcome of the 2 subtypes. Based on the analysis of the clinical data and laboratory information, they proposed absolute and supporting criteria for the diagnosis, which were used in this study. These criteria were validated in a study of Brazilian patients published in where it was shown that 85% of patients with NMO seen in Rio de Janeiro fulfilled the Mayo Clinic criteria, despite the ethnic differences. Of the 71 Rochester, Minnesota, cases, only 6 (8.4%) were nonwhite, while 28 of the 54 patients (51.8%) from Rio de Janeiro were Afro Brazilian. Most of the patients in both case studies 5,21 had normal brain MRI results at onset, extensive inflammatory lesions in the spinal cord, and, from a clinical point of view, severe visual and motor damage, as well as a high prevalence of bilateral visual impairment. These epidemiological, clinical, and laboratory data distinguish RNMO from MS. Recently, Wingerchuk et al 22 proposed a revision to improve the diagnostic properties of NMO criteria. They removed the absolute restriction on CNS involvement beyond the optic nerves and spinal cord and incorporated the NMO-IgG biomarker. One limitation of the present study is that patients with RNMO were not evaluated with serological tests because the cohort predated the availability of these tests. We found a high frequency of women (90%) and Afro Brazilian patients (58.3%). One of the characteristics associated with RNMO is female sex (91%, 4 83%, 5 90%, 6 76%, 7 and 80% 8 ). The syndrome also is more frequent in nonwhite individuals, 22 particularly Asian 23 and African 17 populations. As opposed to MS, which has high prevalence rates in white individuals living in the Northern hemisphere, NMO is a rare syndrome in these regions, constituting less than 1% of demyelinating disease. 24 The frequency of selective and severe involvement of the optic nerve and spinal cord (optic spinal Asian MS) in Japan is 15% to 40%. 23 Data from a national study ( South Atlantic Project, 1997) showed that 14% of the patients with MS living in Rio de Janeiro, in fact, had NMO syndrome. 25 Considering the high rates of mortality and morbidity of NMO, all therapeutic efforts should be considered as possible treatments during the acute phase of ON or TM and as prevention of severe events. Submitted for Publication: September 23, 2006; final revision received February 14, 2007; accepted March 6, Correspondence: Regina Maria Papais-Alvarenga, MD, MSc, PhD, Departamento de Neurologia, UNIRIO, Rua Mariz e Barros 775, Tijuca, Rio de Janeiro, RJ, Brazil (regina_alvarenga@hotmail.com). Financial Disclosure: None reported. Additional Information: This work was conducted in the Neurology course at the Universidade Federal do Estado do Rio de Janeiro. REFERENCES 1. Devic E. Myelite subaigue compliquee de neurite optique. Bull Med. 1894;8: Miyazawa I, Fujihara K, Itoyama Y. Eugene Devic ( ). J Neurol. 2002; 249(3): Kantarci OH, Weinshenker B. Natural history of multiple sclerosis. Neurol Clin. 2005;23(1): O Riordan JI, Gallagher L, Thompson AJ, Howard RS, Milleret DH. Clinical, CSF and MRI findings in Devic s neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996;60(4): Wingerchuk DM, Hogancamp WF, O Brien PC, Peter C, Weinshenker BG. The clinical course of neuromyelitis optica (Devic s syndrome). Neurology. 1999;53 (5): Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, et al. Optic neuromyelitis in Brazilian patients. J Neurol Neurosurg Psychiatry. 2002;73(4): de Seze J, Stojkovic T, Ferriby D, et al. Devic s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002;197(1-2): Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic s neuromyelitis optica. J Neurol. 2004;251(1): Lucchinetti CF, Mandler RN, Mcgavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic s neuromyelitis optica. Brain. 2002;125(Pt 7): Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2004;149(1-2): Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202(4): Alvarenga RMP. SIAPEM. Af J Neurological Sciences. 2003;22(2): Vaughan D. Oftalmologia Geral. 15th ed. São Paulo, Brazil: Atheneu; 2003: Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1991;41(5): Horton JC. Visual disturbances. In: Hauser SL, Kasper DL, Braunwald E, Fauci AS, Longo DL, eds. Harrison s Neurology in Clinical Medicine. New York, NY: McGraw-Hill Professional; 2006: The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1991;109(12): Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol. 1998;55(2): Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol. 2004;61(9): Agostoni E, Frigerio R, Protti A. Controversies in optic neuritis pain diagnosis. Neurol Sci. 2005;26(suppl 2):s75-s Volpe NJ. Optic neuritis: historical aspect. J Neuroophthalmol. 2001;21(4): Papais-Alvarenga RM, Correa JA, Mattielo M, Santos CMM, Puccioni-Sohler M, Alvarenga H. Neuromyelitis optica-nmo (Devic s syndrome): application of the Mayo Clinic criteria for NMO to the ethnically diverse population of Brazil. In: Columbus F, ed. Treatment and Management of Multiple Sclerosis. New York, NY: Nova Publishers; 2005: Wingerchuk DM, Lennon VA, Pittock SJ, Luchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10): Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003;2(2): Cree BAC, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol. 2002;22 (2): Papais-Alvarenga RM, Alves-Leon SV, Miranda Santos CM, Tilbery CP. South Atlantic project: a Brazilian multiple sclerosis trial. In: Arriagada RC, Nogales- Gaete J, eds. Esclerosis Múltiple una Mirada Ibero Pan Americana. Santiago, Chile: Arrynog Ediciones; 2002:
Magnetic Resonance Imaging of Neuromyelitis Optica (Devic s Syndrome)
J Radiol Sci 2012; 37: 45-50 Magnetic Resonance Imaging of Neuromyelitis Optica (Devic s Syndrome) Chien-Chuan Huang Tai-Yuan Chen Tai-Ching Wu Yu-Kun Tsui Te-Chang Wu Wen-Sheng Tzeng Chien-Jen Lin Department
More informationORIGINAL CONTRIBUTION. The Natural History of Recurrent Optic Neuritis
ORIGINAL CONTRIBUTION The Natural History of Recurrent Optic Neuritis Istvan Pirko, MD; Lori K. Blauwet, MD; Timothy G. Lesnick, MSc; Brian G. Weinshenker, MD, FRCP(C) Background: Optic neuritis (ON) may
More informationThe role of anti-aquaporin-4 antibody in Asian patients with multiple sclerosis: Confusions and controversies
Neurology Asia 2007; 12 : 135 139 VIEWS AND REVIEW The role of anti-aquaporin-4 antibody in Asian patients with multiple sclerosis: Confusions and controversies HT Chong, *AG Kermode, CT Tan Department
More informationProfessor Yasser Metwally. Neuromyelitis optica. EPIDEMIOLOGY
180 Professor Yasser Metwally Neuromyelitis optica www.yassermetwally.com N EPIDEMIOLOGY Afro-Caribbean, and South American descent implying underlying genetic mechanisms in the expression of demyelinating
More informationResearch Article Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese Multiple Sclerosis
International Scholarly Research Network ISRN Neurology Volume 211, Article ID 9476, 4 pages doi:1.542/211/9476 Research Article Optic Nerve and Spinal Cord Are the Major Lesions in Each Relapse of Japanese
More informationNeuromyelitis optica (NMO) is characterized as a
Neuromyelitis optica (NMO) is characterized as a severe, relapsing inflammatory disease resulting in vision loss and impaired mobility. As with multiple sclerosis, clinical symptoms result from demyelination
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Neuromyelitis Optica Treatment Analysis of 3 s Denis Bernardi Bichuetti, MD; Enedina Maria Lobato de Oliveira, MD, PhD; Daniel May Oliveira, MD; Nilton Amorin de Souza, MD; Alberto
More informationNeuromyelitis optica (NMO), or Devic s disease, is a rare
Case Report Neuromyelitis Optica (NMO) Abstract NMO is a is a rare entity which involves the central nervous system acting as an inflammatory process by attacking the optic nerve (ON) and longitudinally
More informationNeuromyelitis Optica: A Case Report
Pediatr Neonatol 2010;51(6):347 352 CASE REPORT Neuromyelitis Optica: A Case Report Wei-Chia Chia 1, Jian-Nan Wang 1, Ming-Chi Lai 2 * 1 Department of Family Medicine, Chi-Mei Medical Center, Yong Kang
More informationNew Insights on Optic Neuritis in Young People
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Study New Insights on Optic Neuritis in Young People Sergio Carmona 1, Sandra Barbosa 1 and Maria Laura Ortube 2 * 1 Department of Neuro-ophthalmology, Hospital
More informationAutologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore
Case Reports 26 Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore Koh Yeow Hoay, Pavanni Ratnagopal Abstract Introduction: Neuromyelitis optica (NMO)
More informationWingerchuk et al, Neurol, 2006
Current Understanding of Neuromyelitis Optica Jacqueline A. Leavitt, M.D. Mayo Clinic Rochester, MN I have no financial disclosures 46 y/o F Pain in R temple worse with head movements, resolved in days
More informationMultiple sclerosis in Japan: Nationwide surveys over 30 years
Neurology Asia 28; 13 : 131 143 Multiple sclerosis in Japan: Nationwide surveys over 3 years Jun-ichi Kira, Takaaki Ishizu, Manabu Osoegawa, and The Research Committee of Neuroimmunological Diseases Department
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Markedly Elevated Soluble Intercellular Adhesion Molecule 1, Soluble Vascular Cell Adhesion Molecule 1 Levels, and Blood-Brain Barrier Breakdown in Neuromyelitis Optica Akiyuki Uzawa,
More informationOptic neuromyelitis syndrome in Brazilian patients
PAPER Optic neuromyelitis syndrome in Brazilian patients R M Papais-Alvarenga, C M Miranda-Santos, M Puccioni-Sohler, A M V de Almeida, S Oliveira, C A Basilio De Oliveira, H Alvarenga, C M Poser... See
More informationCOPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED
The Transverse Myelitis Association...advocating for those with acute disseminated encephalomyelitis, neuromyelitis optica, optic neuritis and transverse myelitis ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
More informationNMO-IgG: A specific biomarker for neuromyelitis optica
Disease Markers 22 (2006) 197 206 197 IOS Press NMO-IgG: A specific biomarker for neuromyelitis optica Brian G. Weinshenker a,, Dean M. Wingerchuk d, Sean J. Pittock a,b, Claudia F. Lucchinetti a and Vanda
More informationSawada J, Orimoto R, Misu T, Katayama T, Aizawa H, Asanome A, Takahashi K, Saito T, Anei R, Kamada K, Miyokawa N, Takahashi T, Fujihara K, Hasebe N.
Mult Scler (2014.9) 20(10):1413-1416. A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion.
More informationTitle Neuromyelitis Optica in Japanese Author(s) TANAKA, Yuji Citation [Internal Medicine] vol.[50] no.[ Issue Date 2011 Rights The Japanese Society of Internal 内科学会 ) Version 出版社版 (publisher version)
More informationActualização no diagnóstico e tratamento das doenças desmielinizantes na infância. Silvia Tenembaum
Actualização no diagnóstico e tratamento das doenças desmielinizantes na infância Silvia Tenembaum Acquired CNS inflammatory/demyelinating disorders: Background information More frequent in children than
More informationMYELITIS. A Mochan Neurology
MYELITIS A Mochan Neurology ATM MS LETM NMOSD ATM LETM MS NMOSD Acute Transverse Myelitis Longitudinally Extensive Transverse Myelitis Multiple Sclerosis Neuromyelitis Optica Spectrum Disorders ATM ADEM
More informationClinical prospective study of visual function in patients with acute optic neuritis
Journal of the Formosan Medical Association (2013) 112, 87e92 Available online at www.sciencedirect.com journal homepage: www.jfma-online.com ORIGINAL ARTICLE Clinical prospective study of visual function
More informationMRI Imaging of Neuromyelitis Optica
July 2009 MRI Imaging of Neuromyelitis Optica Jenna Nolan, Harvard Medical School Year III Gillian Lieberman, MD Our Patient: Initial Presentation J.H. is a 29 year-old woman who presents with acute vision
More informationNMO IgG (Aquaporin-4) autoantibodies in immune-mediated optic neuritis
NMO IgG (Aquaporin-4) autoantibodies in immune-mediated optic neuritis A Petzold, Sean J Pittock, Vanda Lennon, Cosimo Maggiore, B G Weinshenker, Gordon T Plant To cite this version: A Petzold, Sean J
More informationSalintip Kunadison MD, Chaiwiwat Tungkasereerak MD, Surin Saetang MD, Pawut Mekawichai MD
Neurology Asia 2018; 23(1) : 55 59 Comparison of clinical features between aquaporin-4 antibody seropositive and seronegative patients in neuromyelitis optica and neuromyelitis optica spectrum disorder
More informationBlood Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability
The Journal of International Medical Research 2012; 40: 1483 1491 Blood Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability
More informationMRI features and anti-aqp4 antibody status in Idiopathic inflammatory demyelinating CNS disease (IIDCD) in Thai patients
Neurology Asia 2013; 18(1) : 73 81 MRI features and anti-aqp4 antibody status in Idiopathic inflammatory demyelinating CNS disease (IIDCD) in Thai patients 1 Naraporn Prayoonwiwat MD, 2 Orasa Chawalparit
More informationSetting the Scene: Neuromyelitis Optica epidemiology, population variability, subgroups: relapsing/monophasic, Ab +ve/-ve, NMO/SD, treated/untreated
UK Nationally Commissioned NMO team Setting the Scene: Neuromyelitis Optica epidemiology, population variability, subgroups: relapsing/monophasic, Ab +ve/-ve, NMO/SD, treated/untreated Jackie Palace Disclosures
More informationHeterogeneity of Demyelinating Disease: Definitions and Overlap Overview
Heterogeneity of Demyelinating Disease: Definitions and Overlap Overview Brian Weinshenker, MD, FRCP(C) Disclosures Royalties related to patent for discovery of NMO-IgG licensed to RSR Ltd; Oxford University
More informationNeuromyelitis optica and neuromyelitis optica-igg seropositivity in Saudis with demyelinating diseases of the central nervous system
Neurology Asia 2014; 19(3) : 295 300 Neuromyelitis optica and neuromyelitis optica-igg seropositivity in Saudis with demyelinating diseases of the central nervous system 1,2 Ali M Al-Khathaami FRCPC, 2
More informationThe use of AQP4-antibody testing in diagnosis Thai patients with neuromyelitis optica
Neurology Asia 2014; 19(4) : 375 385 The use of AQP4-antibody testing in diagnosis Thai patients with neuromyelitis optica 1,2 Sasitorn Siritho MD, 3 Metha Apiwattanakul MD, 1 Naraporn Prayoonwiwat MD
More informationPediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study
Pediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study Magnus Spangsberg Boesen November, 2016 Supervisors: P. Born, P. Uldall, M. Blinkenberg, M. Magyari, F. Sellebjerg
More informationOcular Oscillations and Transient Oscillopsia in Neuromyelitis Optica
Elmer ress Case Report J Neurol Res. 2014;4(5-6):145-149 Ocular Oscillations and Transient Oscillopsia in Neuromyelitis Optica Nitin Nema a, c, Abha Verma a, Urvija Choudhary a, Pramod Sakhi b Abstract
More informationResearch Paper: Tapering Oral Steroid Treatment After IV Methylprednisolone Pulse Therapy in Demyelinating Optic Neuritis
Caspian Journal of Neurological Sciences "Caspian J Neurol Sci" Journal Homepage: http://cjns.gums.ac.ir Research Paper: Tapering Oral Steroid Treatment After IV Methylprednisolone Pulse Therapy in Demyelinating
More informationRSR RSR RSR RSR RSR. ElisaRSR AQP4 Ab RSR. Aquaporin-4 Autoantibody Assay Kit
To aid diagnosis of Neuromyelitis Optica (NMO) and NMO spectrum disorder (NMOSD) To confirm diagnosis before initial treatment of patients with demyelinating inflammatory disease NMO, NMOSD and AQP4 Elisa
More informationORIGINAL CONTRIBUTION. Painful Tonic Spasm in Neuromyelitis Optica. Incidence, Diagnostic Utility, and Clinical Characteristics
ORIGINAL CONTRIBUTION Painful Tonic Spasm in Neuromyelitis Optica Incidence, Diagnostic Utility, and Clinical Characteristics Sung-Min Kim, MD; Min Jin Go, MS; Jung-Joon Sung, MD, PhD; Kyung Seok Park,
More informationMyelitis. Case 2. History. Examination. Mahtab Ghadiri
Case 2 Myelitis Mahtab Ghadiri History A 42-year-old man presented to the emergency department with altered sensation in the lower limbs and difficulty ambulating. He first noted paresthesia in his feet
More informationObjective: To assess the evidence for diagnostic tests and therapies for transverse myelitis (TM) and make evidence-based recommendations.
Published Ahead of Print on December 7, 2011 as 10.1212/WNL.0b013e31823dc535 SPECIAL ARTICLE Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis Report of the Therapeutics
More informationPatologie infiammatorie encefaliche e midollari
Patologie infiammatorie encefaliche e midollari Maria Laura Stromillo Department of Medicine, Surgery and Neuroscience Inflammatory disorders of the CNS NMOSD ADEM Multiple Sclerosis Neuro-Myelitis Optica
More informationNMOSD: CURRENT AND EMERGING THERAPIES AND STRATEGIES
NMOSD: CURRENT AND EMERGING THERAPIES AND STRATEGIES Dean M. Wingerchuk, MD, MSc, FRCP(C) Mayo Clinic Scottsdale, AZ Neuromyelitis optica (NMO; Devic s syndrome) consists of optic neuritis and transverse
More informationThe Etiological Spectrum of Acute Sensory Myelitis
Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2015;11(3):227-233 / http://dx.doi.org/10.3988/jcn.2015.11.3.227 ORIGINAL ARTICLE Jae-Won Hyun a,c Jee Young Kim b Kyung Gyu Choi a Ho Jin
More informationORIGINAL CONTRIBUTION. Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression
ORIGINAL CONTRIBUTION Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression Sean J. Pittock, MD; Brian G. Weinshenker, MD; Claudia F. Lucchinetti, MD; Dean M. Wingerchuk,
More informationLoss of Aquaporin-4 in Active Perivascular Lesions in Neuromyelitis Optica: A Case Report
Tohoku J. Exp. Med., 2006, Loss 209, of Aquaporin-4 269-275 in the Lesions of Neuromyelitis Optica 269 Loss of Aquaporin-4 in Active Perivascular Lesions in Neuromyelitis Optica: A Case Report Case Report
More informationPMH: No medications; Immunizations UTD No hospitalizations or surgeries Speech Delay. Birth Hx: 24 WGA, NICU x6 months
HPI: 6 months of weakness and parathesias- originally in both feet x 2-3 months, then resolved. Now with parathesias and weakness in fingers x 1 week. Seen by podiatrist and given custom in-soles 1 month
More informationTitle: Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases.
Author's response to reviews Title: Recurrent myelitis after allogeneic stem cell transplantation. Report of two cases. Authors: Martin Voss (Martin.Voss@kgu.de) Felix Bischof (Felix.Bischof@uni-tuebingen.de)
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker, II, MD University of Alabama at Birmingham June 2, 2016 DISCLOSURES Research Support: Biogen Idec; Department of
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset
ORIGINAL CONTRIBUTION Multiple Sclerosis That Is Progressive From the Time of Onset Clinical Characteristics and Progression of Disability P. B. Andersson, MBChB, DPhil; E. Waubant, MD; L. Gee, MPH; D.
More informationThe Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis Mithu Storoni 1,2 *, Axel Petzold 1,3, Gordon T. Plant 1,2 1 The National
More informationNeuromyelitis optica mimics the morphology of spinal cord tumors
The Turkish Journal of Pediatrics 2016; 58: 309-314 Case Report Neuromyelitis optica mimics the morphology of spinal cord tumors İlknur Erol 1, Murat Özkale 2, Tülin Savaş 1, Özlem Alkan 3, Melih Çekinmez
More informationNeurological Assessment for Multiple Sclerosis and Extended Disability Scale Score
Neurological Assessment for Multiple Sclerosis and Extended Disability Scale Score This section should only be completed by a neurologist or MD / ROD (Medical Doctor / Resident on Duty) involved in the
More informationClinical Study The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies
Multiple Sclerosis International Volume 0, Article ID 780, 5 pages doi:0.55/0/780 Clinical Study The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies
More informationImmune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica
Arq Neuropsiquiatr 200;(-B):7-4 Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica Soniza Vieira Alves-Leon 1,4, Maria Lucia Vellutini Pimentel 2, Gabrielle
More informationSevere visual loss due to optic neuritis (ON) is the most
Ocular Oscillations in the Neuromyelitis Optica Spectrum Rabih Hage, Jr, MD, Harold Merle, MD, Séverine Jeannin, MD, Philippe Cabre, MD Abstract: Four French West Indian women complained of oscillopsia
More informationThe Incidence and Prevalence of Neuromyelitis Optica
The Incidence and Prevalence of Neuromyelitis Optica A Systematic Review Ruth Ann Marrie, MD, PhD; Caroline Gryba, BSc Interest in neuromyelitis optica (NMO) has increased substantially over the last few
More informationSoliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018
Soliris in NMOSD Phase 3 PREVENT Study Topline Results September 24, 2018 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationRole Of Various Factors In The Treatment Of Optic Neuritis----A Study Abstract Aim: Materials & Methods Discussion: Conclusion: Key words
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 9 Ver. X (September). 2016), PP 51-57 www.iosrjournals.org Role Of Various Factors In The Treatment
More informationSeema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW
Seema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW DISCLOSURES I have no industry relationships to disclose. I will not discuss off-label use. OBJECTIVES: TRANSVERSE MYELITIS Review
More informationThe natural history of optic neuritis in Asian patients: An observational cohort study
Neurology Asia 2017; 22(4) : 341 348 The natural history of optic neuritis in Asian patients: An observational cohort study 1 BHA Seah, 1 SLC Tow, 2 Ong KCB Ong, 3 CC Yang, 4 CP Tsai, 5 KH Lee, 5 BJ Kim,
More informationHeterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese
doi:10.1093/brain/awm027 Brain (2007), 130,1206^1223 Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese Takeshi Matsuoka, 1 Takuya Matsushita, 1 Yuji Kawano,
More informationLate-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population
Mao et al. BMC Neurology (2015) 15:160 DOI 10.1186/s12883-015-0417-y RESEARCH ARTICLE Open Access Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population
More informationDevic s syndrome: a case report WarumpornLimuntachai. Medical Student in Emergency Department, Ramathibodi Hospital, Bangkok, Thailand
Devic s syndrome: a case report WarumpornLimuntachai Medical Student in Emergency Department, Ramathibodi Hospital, Bangkok, Thailand Abstract Objective: to report a case of Devic s syndrome, emphasizing
More informationMagnetic Resonance Imaging in the Acquired Demyelinating Disorders: A Pediatric Cohort Study
Journal of Pharmacy and Pharmacology 6 (2018) 20-31 doi: 10.17265/2328-2150/2018.01.003 D DAVID PUBLISHING Magnetic Resonance Imaging in the Acquired Demyelinating Disorders: A Pediatric Cohort Study Santa
More informationLow sensitivity of McDonald MRI criteria in the diagnosis of multiple sclerosis among Asians
Neurology Asia 2006; 11 : 129 133 Low sensitivity of McDonald MRI criteria in the diagnosis of multiple sclerosis among Asians 1 Heng-Thay CHONG MRCP, 1 Norlisah RAMLI FRCR, 2 Kwang-Ho LEE MD, 2 Byung-Joon
More informationClinical differences between young and older patients with optic neuritis
Original Article Page 1 of 5 Clinical differences between young and older patients with optic neuritis Wenjing Luo 1 *, Qiu-Shui Huang 2 *, Jian-Feng He 2, Min Han 1, Bo Liu 1, Yi Du 2 1 The Cadre Ward
More informationClinical improvement in a patient with neuromyelitis optica following therapy with the anti-il-6 receptor monoclonal antibody tocilizumab
Mod Rheumatol (13) 3:87 831 DOI 1.17/s1165-1-715-9 CASE REPORT Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-il-6 receptor monoclonal antibody tocilizumab
More informationMRI and differential diagnosis in patients suspected of having MS
Andrea Falini Italy MRI and differential diagnosis in patients suspected of having MS IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Outline of presentation - Diagnostic criteria
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationRehabilitation of Neuromyelitis Optica (Devic s Syndrome): 3 Case Reports
Thomas Jefferson University Jefferson Digital Commons Department of Rehabilitation Medicine Faculty Papers Department of Rehabilitation Medicine Winter 2-1-2008 Rehabilitation of Neuromyelitis Optica (Devic
More informationDisease of Myelin. Reid R. Heffner, MD Distinguished Teaching Professor Emeritus Department of Pathology and Anatomy January 9, 2019
Disease of Myelin Reid R. Heffner, MD Distinguished Teaching Professor Emeritus Department of Pathology and Anatomy January 9, 2019 1 I HAVE NO CONFLICTS OF INTEREST OR DISCLOSURES TO DECLARE. I HAVE NO
More informationNeuromyelitis optica: a challenging diagnosis at secondary hospital
53 Autopsy and Case Reports 2013; 3(1): 53-61 Article / Clinical Case Reports Artigo / Relato de Caso Clínico Neuromyelitis optica: a challenging diagnosis at secondary hospital Anna Paula Romero de Oliveira
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationPATIENTS WITH MULTIPLE SCLEROSIS
3 PATIENTS WITH MULTIPLE SCLEROSIS PREFER EARLY DIAGNOSIS Abstract The new diagnostic criteria for multiple sclerosis (MS) allow for a definite diagnosis in earlier stages of disease. Yet, clinicians may
More informationParaparesis. Differential Diagnosis. Ran brauner, Tel Aviv university
Paraparesis Differential Diagnosis Ran brauner, Tel Aviv university Definition Loss of motor power to both legs Paraparesis (paraplegia) refers to partial (- paresis) or complete (-plegia) loss of voluntary
More informationMRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE
MRI in Differential Diagnosis CMSC, June 2, 2016 Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC Disclosures Speaking, consulting, and/or
More informationOpticospinal multiple sclerosis in Japanese
Neurology Asia 2008; 13 : 167 173 Opticospinal multiple sclerosis in Japanese Jun-ichi Kira, Takuya Matsushita, Noriko Isobe, Takaaki Ishizu Department of Neurology, Neurological Institute, Graduate School
More informationOptic neuritis in Singapore
667 Original Article Optic neuritis in Singapore Lim S A, Goh K Y, Tow S, Fu E, Wong T Y, Seah A, Tan C, Cullen J F ABSTRACT Introduction: Optic neuritis (ON) is the commonest optic neuropathy encountered
More informationORIGINAL CONTRIBUTION. Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica
ORIGINAL CONTRIBUTION Microcystic Inner Nuclear Layer Abnormalities and Neuromyelitis Optica Jeffrey M. Gelfand, MD; Bruce A. Cree, MD, PhD, MRC; Rachel Nolan, BA; Sam Arnow, BS; Ari J. Green, MD, MCR
More informationAnalysis of prognostic significance of clinical and paraclinical indices in case of different types of acute disseminated encephalomyelitis course.
1 2 Analysis of prognostic significance of clinical and paraclinical indices in case of different types of acute disseminated encephalomyelitis course. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
More informationAtypical presentations of neuromyelitis optica
View and review Arq Neuropsiquiatr 2011;69(5):824-828 Atypical presentations of neuromyelitis optica Douglas Sato 1,2, Kazuo Fujihara 3 ABSTRACT Neuromyelitis optica (NMO) is an inflammatory disease of
More informationDose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
Jiao et al. BMC Neurology (2018) 18:47 https://doi.org/10.1186/s12883-018-1056-x RESEARCH ARTICLE Open Access Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum
More informationAn overview of NMO Spectrum Disorder and the diagnostic utility of anti-nmo antibodies
The Hong Kong College of Pathologists, Incorporated in Hong Kong with Limited Liability Volume 13, Issue 1 January 2018 Editorial note: NMOSD is an immune mediated demyelinating disease. Though its clinical
More informationNIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2012 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2011 July ; 68(7): 870 878. doi:10.1001/archneurol.2011.34. Beneficial Plasma Exchange Response in CNS Inflammatory Demyelination
More informationMULTIPLE SCLEROSIS MSJ
431727MSJ18610.1177/1352458511431727Estiasari et al.multiple Sclerosis Journal 2012 Research Paper MULTIPLE SCLEROSIS JOURNAL MSJ Comparison of clinical, immunological and neuroimaging features between
More informationIsolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis
AJNR Am J Neuroradiol 21:702 706, April 2000 Isolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis Mar Tintoré, Alex
More informationMULTIPLE SCLEROSIS PROFILE
MULTIPLE SCLEROSIS PROFILE What is Multiple Sclerosis? Multiple sclerosis (MS) is a chronic, inflammatory disease of unknown etiology that involves an immune-mediated attack on the central nervous system
More informationORIGINAL CONTRIBUTION. Long-term Follow-up of Acute Partial Transverse Myelitis
ORIGINAL CONTRIBUTION Long-term Follow-up of Acute Partial Transverse Myelitis Bertrand Bourre, MD; Hélène Zéphir, MD; Jean-Claude Ongagna, CRA; Charlotte Cordonnier, MD, PhD; Nicolas Collongues, MD; Stephanie
More informationA trial of corticotrophin gelatin injection in
Journal of Neurology, Neurosurgery, and Psychiatry, 1974, 37, 869-873 A trial of corticotrophin gelatin injection in acute optic neuritis A. N. BOWDEN, P. M. A. BOWDEN, A. I. FRIEDMANN, G. D. PERKIN, AND
More informationEndpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK
Endpoints in a treatment trial in NMO: Clinician s view Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK 1 The greatest challenge to any thinker is stating the problem in a way that will
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org How
More informationClinical insights for early detection of acute transverse myelitis in the emergency department
Clin Exp Emerg Med 2015;2(1):44-50 http://dx.doi.org/10.15441/ceem.14.034 Clinical insights for early detection of acute transverse myelitis in the emergency department Yo Huh, Eun-Jung Park, Ju-Won Jung,
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker II, MD University of Alabama at Birmingham Birmingham VA Medical Center May 29, 2014 DISCLOSURES Salary/Research:
More informationDiffuse myelitis in a 9-month-old infant: case report and review of the literature
230 La Revue de Santé de la Méditerranée orientale, Vol. 15, N 1, 2009 Case report Diffuse myelitis in a 9-month-old infant: case report and review of the literature O. Hüdaoglu,¹ U. Yis,¹ S. Kurul,¹ H.
More informationGILENYA (fingolimod) oral capsule
GILENYA (fingolimod) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationClinically isolated syndromes (CIS) may
RECOGNIZING AND MANAGING THE CLINICALLY ISOLATED SYNDROME* Steven L. Galetta, MD ABSTRACT Clinically isolated demyelinating syndromes, such as optic neuritis, transverse myelitis, and brain-stem disorders,
More informationCLINICAL SPECTRUM OF MULTIPLE SCLEROSIS AT A TERTIARY CARE HOSPITAL IN PAKISTAN
Original Article CLINICAL SPECTRUM OF MULTIPLE SCLEROSIS AT A TERTIARY CARE HOSPITAL IN PAKISTAN Hoori Shahwar 1, Syed Wasim Akhter 2, Shaukat Ali 3 ABSTRACT Objective: To assess the clinical presentation
More informationMULTIPLE SCLEROSIS Update
MULTIPLE SCLEROSIS Update E. Torage Shivapour, M.D. Clinical Professor Department of Neurology University of Iowa Hospitals & Clinics Disclosures I do not have any disclosures. Multiple Sclerosis Most
More informationPearls, Pitfalls and Advances in Neuro-Ophthalmology
Pearls, Pitfalls and Advances in Neuro-Ophthalmology Nancy J. Newman, MD Emory University Atlanta, GA Consultant for Gensight Biologics, Santhera Data Safety Monitoring Board for Quark AION Study Medical-legal
More informationReview Article Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System
Neurology Research International Volume 2012, Article ID 460825, 13 pages doi:10.1155/2012/460825 Review Article Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System Jiwon
More informationMRI diagnostic criteria for multiple sclerosis: an update
MRI diagnostic criteria for multiple sclerosis: an update Poster No.: C-0285 Congress: ECR 2013 Type: Educational Exhibit Authors: L. Valls Masot, A. M. Quiles Granado, J. Puig Alcántara, L. RamióTorrentà,
More informationNeurological update: MOG antibody disease
https://doi.org/10.1007/s00415-018-9122-2 NEUROLOGICAL UPDATE Neurological update: MOG antibody disease Ray Wynford Thomas 1,2 Anu Jacob 3 Valentina Tomassini 1,2,4 Received: 17 August 2018 / Revised:
More information